Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on UDG HEALTHCARE PLC. We currently have 21 research reports from 2 professional analysts.
|21Mar17 15:03||RNS||Holding(s) in Company|
|06Mar17 11:46||RNS||Holding(s) in Company|
|27Feb17 16:00||RNS||Holding(s) in Company|
|16Feb17 14:46||RNS||Director Declaration|
|07Feb17 15:45||RNS||Result of AGM|
|07Feb17 07:00||RNS||Board Appointment|
|07Feb17 07:00||RNS||1st Quarter Trading Update|
Frequency of research reports
Research reports on
UDG HEALTHCARE PLC
UDG HEALTHCARE PLC
N+1 Singer - UDG Healthcare - Strong Q1 update
07 Feb 17
A strong Q1 update reassures that UDG is capitalising on the twin investment theses of structural growth in the pharma outsourcing market and mix driven margin enhancement. The company is guiding to +13-16% EPS growth at CER, driven by good organic growth and recent acquisitions. The health net cash position also means UDG retains significant firepower for further deals, which should lead to further upgrade momentum in due course. We are reviewing our forecasts for the change in reporting currency and will reissue these shortly.
N+1 Singer - Morning Song 24-11-2016
24 Nov 16
Abzena (ABZA LN) Positive Phase I/II data on Abzena inside programme OPN-305 | Actual Experience (ACT LN) 3-yr framework agreement with Accenture | CVS Group (CVSG LN) Strong AGM prompts double-digit upgrades | Euromoney Institutional Investor (ERM LN) No change to outlook | Futura Medical (FUM LN) Forecast update post equity capital raise | Marston’s (MARS LN) Solid finals and reassuring tenor | Sigma Capital Group (SGM LN) Milestone reached: 1000th PRS home completed and let | UDG Healthcare (UDG LN) In line prelims, outlook intact
N+1 Singer - UDG Healthcare - First acquisition heralds start of an upgrade cycle
25 Oct 16
UDG’s first material acquisition since the disposal of the Supply Chain division in April gives some flavour of the direction ahead. It is paying just over 8x EBITDA for a fast growing and high margin business, which will bring a unique service offering into the Ashfield mix. Although FX and opex related to the Future Fit programme temper our EPS upgrades to 3%, we expect further accretive deals to follow. We increase our TP to 746p and reiterate our Buy recommendation.
Updating estimates on H116, FX moves
21 Jul 16
We are updating our forecasts for UDG on the back of solid H116 results, the completion of the sale of the drug distribution business and recent pronounced currency moves. While providing a sufficient cash cushion in the current volatile market conditions, the divestment will allow increased flexibility for the company to deliver on its already successful track record of acquisitions. We raise our DCF valuation from £5.21 to £6.45/share.
07 Jun 16
Carclo (CAR LN) Core divisions remain strong | Goals Soccer Centres (GOAL LN) Time to take a serious look | Gooch & Housego (GHH LN) H1 decline as expected, FY guidance unchanged | Herald Investment Trust (HRI LN) Good long term performance | IDOX (IDOX LN) Strong interims and confident outlook | iomart Group (IOM LN) Solid progression with 9% organic growth in Cloud | Minds + Machines Group (MMX LN) .vip significant momentum continues | UDG Healthcare (UDG LN) Growing share in a growth market | Vp (VP/ LN) A strong conclusion to a very busy year | WYG (WYG LN) FY16 results in line, momentum building
N+1 Singer - Morning Song 21-03-2017
21 Mar 17
accesso Technology (ACSO LN) Full year results in line, but key trading months still ahead | Augean (AUG LN) Double digit growth in ’16, good start to ‘17 | Earthport (EPO LN) Interims show continued top line strength | Goals Soccer Centres (GOAL LN) Good momentum under new team. It’s now all about delivery | IQE (IQE LN) FY’16 results prompt further upgrades | Microsaic Systems (MSYS LN) Challenges in 2016, strategy remains in place | mporium Group (MPM LN) Funds raised to help execute strategy | RhythmOne (RTHM LN) Dawn of the independents | ScS Group (SCS LN) Strong progress on key growth initiatives albeit comps now toughen | Sinclair Pharma (SPH LN) FY results: EBITDA ahead, Instalift™ gaining pace | Vectura Group (VEC LN) FY (9-month) results
N+1 Singer - EKF Diagnostics - Final results & potential buy back
20 Mar 17
FY16 prelims are slightly ahead of our latest expectations, those having been increased materially over the course of H2’16 as the strength of the recovery in trading became apparent. In order to maximise shareholder value, the directors are currently examining a potential break up of the group. This would also involve a delisting from AIM. A buy back offer at 21.5p would therefore be made to those investors that wish to exit now rather than holding their shares for the two years plus it would likely take to achieve a potentially higher realisation value for the businesses.
Good results, but further restructuring complex for investors
20 Mar 17
EKF Diagnostics FY 2016 results are slightly ahead of expectations, with both higher revenue and better EBITDA. Management has also announced plans to split the company into two separate companies, Point of Care and Laboratory Diagnostics, with the prospect of a delisting to manage the process. The primary metric for valuation of the two businesses is different consequently we believe that the separation is likely to generate significant value. However, in anticipation of the volatility likely given the restructuring announced this morning, despite the strength of the results, we reduce our recommendation to HOLD and maintain our 21p target price.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017